ライフサイエンスコーパス: Guillain-Barre syndrome

1 eutralization of autoantibodies in the fatal Guillain-Barre syndrome.

2 orldwide and is implicated in development of Guillain-Barre syndrome.

3 possible association between vaccination and Guillain-Barre syndrome.

4 nts safety concerns about the development of Guillain-Barre syndrome.

5 as suspended because of an increased risk of Guillain-Barre syndrome.

6 ions, including irritable bowel syndrome and Guillain-Barre syndrome.

7 frequent antecedent of autoimmune neuropathy Guillain-Barre syndrome.

8 s as well as cases of the autoimmune disease Guillain-Barre syndrome.

9 nal neuropathy that closely resembled axonal Guillain-Barre syndrome.

10 nstem encephalitis or those with overlapping Guillain-Barre syndrome.

11 ical features in paralytic rabies and axonal Guillain-Barre syndrome.

12 in some cases of Miller Fisher syndrome and Guillain-Barre syndrome.

13 corticosteroids, in hastening recovery from Guillain-Barre syndrome.

14 s human diseases, including microcephaly and Guillain-Barre syndrome.

15 es mapping their relationship to subtypes of Guillain-Barre syndrome.

16 its characteristic of multiple sclerosis and Guillain-Barre syndrome.

17 o a form of neuromuscular paralysis known as Guillain-Barre syndrome.

18 microcephaly, congenital malformations, and Guillain-Barre syndrome.

19 on in acute peripheral neuropathies, such as Guillain-Barre syndrome.

20 lipopolysaccharide has been associated with Guillain-Barre syndrome.

21 oimmune neuritis (EAN) is an animal model of Guillain-Barre syndrome.

22 nfectious sequelae of reactive arthritis and Guillain-Barre syndrome.

23 utoimmune neuritis (EAN), an animal model of Guillain-Barre syndrome.

24 e compatible with a role in the causation of Guillain-Barre syndrome.

25 onset of a syndrome diagnosed clinically as Guillain-Barre syndrome.

26 IVGG is a recognised treatment for Guillain-Barre syndrome.

27 etiological factor in multiple sclerosis and Guillain-Barre syndrome.

28 isease progression in multiple sclerosis and Guillain-Barre syndrome.

29 jejuni infection is associated with "axonal" Guillain-Barre syndrome.

30 myelinating polyneuropathy (AIDP) pattern of Guillain-Barre syndrome.

31 as is linked to congenital birth defects and Guillain-Barre syndrome.

32 the cauda equina was similar to that seen in Guillain-Barre syndrome.

33 microcephaly, congenital malformations, and Guillain-Barre syndrome.

34 other severe neurological diseases, such as Guillain-Barre syndrome.

35 demyelinating polyneuropathy subtype of the Guillain-Barre syndrome.

36 ng evidence for Zika virus infection causing Guillain-Barre syndrome.

37 irus (ZIKV) infection has been linked to the Guillain-Barre syndrome.

38 rus and dengue virus infection in developing Guillain-Barre syndrome.

39 rders, including microcephaly in infants and Guillain-Barre syndrome.

40 Cases of acute ZIKV are also associated with Guillain-Barre syndrome.

41 e care beds capacity to manage patients with Guillain-Barre syndrome.

42 5 accompanied by congenital microcephaly and Guillain-Barre syndrome.

43 e of the infection in the development of the Guillain-Barre syndrome.

44 with ZIKV infection before the onset of the Guillain-Barre syndrome.

45 an etiologic agent of fetal microcephaly and Guillain-Barre syndrome.

46 possible association between Zika virus and Guillain-Barre syndrome.

47 e patient because of multiorgan failure with Guillain-Barre syndrome.

48 ment disorder, 1 had encephalitis, and 1 had Guillain-Barre syndrome.

49 er from acute demyelinating diseases such as Guillain-Barre syndrome.

50 orldwide and is implicated in development of Guillain-Barre syndrome.

51 ccines used in the USA increased the risk of Guillain-Barre syndrome.

52 gical complications of the Miller-Fisher and Guillain-Barre syndromes.

53 mboembolic events, autoimmune disorders, and Guillain-Barre syndrome; 0.1 for anaphylaxis and death;

54 We interviewed 180 of 273 adults with the Guillain-Barre syndrome; 15 declined to participate, and

55 e Americas has unveiled microcephaly (1) and Guillain-Barre syndrome(2,3) as ZIKV-associated neurolog

56 2 patients) or acute polyradiculoneuropathy (Guillain-Barre syndrome) (4/12).

57 Among the 68 patients with the Guillain-Barre syndrome, 50% were found to have bilatera

58 esses on the physician differential included Guillain-Barre syndrome (99 cases) and myasthenia gravis

59 evidence now exists that axonal subtypes of Guillain-Barre syndrome, acute motor axonal neuropathy (

60 rs found no evidence of an increased risk of Guillain-Barre syndrome after seasonal influenza vaccine

61 ring project identified an increased risk of Guillain-Barre syndrome after vaccination; however, some

62 Surges in congenital defects and Guillain-Barre syndrome alerted the world to the danger

63 immunoglobulin is an effective treatment for Guillain-Barre syndrome, although the mechanism of actio

64 uals was vaccinated in the UK, 21.5 cases of Guillain-Barre syndrome and 5.75 cases of sudden death w

65 The reporting rates of Guillain-Barre syndrome and anaphylaxis after TIV-HD rec

66 porting rates were calculated for reports of Guillain-Barre syndrome and anaphylaxis.

67 and unexpected clinical outcomes, including Guillain-Barre syndrome and birth defects, has brought a

68 matory CD4(+) T cells that is reminiscent of Guillain-Barre syndrome and chronic inflammatory demyeli

69 ral neuropathy that resembles human diseases Guillain-Barre syndrome and chronic inflammatory demyeli

70 i-tubulin autoantibodies are associated with Guillain-Barre syndrome and chronic inflammatory demyeli

71 In Guillain-Barre syndrome and CIDP intravenous immunoglobu

72 e Zika virus (ZIKV) has been associated with Guillain-Barre syndrome and fetal abnormalities, but the

73 ction of the link between ZIKV infection and Guillain-Barre syndrome and fetal neurological defects,

74 eports of a preceding respiratory illness in Guillain-Barre syndrome and has important implications f

75 view the occurrence and clinical features of Guillain-Barre syndrome and its variant, the Miller Fish

76 sequelae such as hemolytic uremic syndrome, Guillain-Barre syndrome and malnutrition.

77 treatment is beneficial in CIDP, but not in Guillain-Barre syndrome and may worsen MMNCB.

78 of recent outbreaks and concerning links to Guillain-Barre syndrome and microcephaly are incompletel

79 d complications of ZIKV infection, including Guillain-Barre syndrome and microcephaly, potential inte

80 ditions with a primary immune basis, such as Guillain-Barre syndrome and multiple sclerosis.

81 of therapeutic plasma exchange for managing Guillain-Barre syndrome and myasthenia gravis were publi

82 uch as acute disseminated encephalomyelitis, Guillain-Barre syndrome and neuromyelitis optica.

83 severe neuropathology in neonates as well as Guillain-Barre syndrome and other neurologic disorders i

84 were evidences of two severe adverse events (Guillain-Barre Syndrome and paralysis) present in TIV.

85 casionally are similar to those described in Guillain-Barre syndrome and suggest a possible relations

86 t differ significantly between patients with Guillain-Barre syndrome and those in the two control gro

87 Two patients developed Guillain-Barre syndrome, and 3 of 4 pregnancies had adve

88 n a proportion of patients with motor axonal Guillain-Barre syndrome, and also provide an explanation

89 e (MFS) variant of the paralytic neuropathy, Guillain-Barre syndrome, and are believed to be the prin

90 patients with chronic motor neuropathies and Guillain-Barre syndrome, and GQ1b/ disialosyl antisera a

91 ion that mimic botulism, such as stroke, the Guillain-Barre syndrome, and myasthenia gravis.

92 MENTARY ON THIS ARTICLE : In axonal forms of Guillain-Barre syndrome, anti-ganglioside antibodies bin

93 de, collaborative studies of the spectrum of Guillain-Barre syndrome are accruing data for clinical a

94 Diseases such as multiple sclerosis and Guillain-Barre syndrome are characterized not only by wi

95 Under the umbrella term of Guillain-Barre syndrome are several recognisable variant

96 that some patients with severe motor-sensory Guillain-Barre syndrome, as defined clinically, have pre

97 europathy syndromes, some of which may mimic Guillain-Barre syndrome, as many will have a metabolic a

98 The relative risk of the Guillain-Barre syndrome associated with vaccination, adj

99 ith a specific Penner serotype, and 14 of 16 Guillain-Barre syndrome-associated isolates tested in th

100 A total of 68 patients with the Guillain-Barre syndrome at six Colombian hospitals were

101 The modest risk of Guillain-Barre syndrome attributed to vaccination is con

102 of serotype O:19 strains from patients with Guillain-Barre syndrome but not in cores of nonneuropath

103 ture confirms the use of plasma exchange for Guillain-Barre syndrome but suggests that inadequate evi

104 Features initially suggested Guillain-Barre syndrome, but botulinum toxin was identif

105 early stages of the disease, and that axonal Guillain-Barre syndrome can follow C. jejuni infection.

106 e in access to nutrients; an outbreak of the Guillain-Barre syndrome caused by lack of chlorination c

107 er Fisher syndrome is a localized variant of Guillain-Barre syndrome, characterized by ophthalmoplegi

108 2 g/kg is effective as first-line therapy in Guillain-Barre syndrome, chronic inflammatory demyelinat

109 rts the use of intravenous immunoglobulin in Guillain-Barre syndrome, chronic inflammatory demyelinat

110 , nonlength-dependent neuropathies including Guillain-Barre syndrome, chronic inflammatory demyelinat

111 iffuse, nonlength-dependent neuropathies are Guillain-Barre syndrome, chronic inflammatory demyelinat

112 in the western hemisphere has been linked to Guillain-Barre syndrome, congenital microcephaly, and de

113 Guillain-Barre syndrome consists of at least four subtyp

114 Guillain-Barre syndrome developed following infliximab t

115 In addition, 15 patients in whom Guillain-Barre syndrome developed following TNFalpha ant

116 om the Miller Fisher syndrome variant of the Guillain-Barre syndrome developed while he was receiving

117 case-control study, cases were patients with Guillain-Barre syndrome diagnosed at the Centre Hospital

118 lmonella, Yersinia, and Shigella organisms), Guillain-Barre syndrome (due to Campylobacter organisms)

119 documented by RT-PCR among patients with the Guillain-Barre syndrome during the outbreak of ZIKV infe

120 stem represents a useful means of monitoring Guillain-Barre syndrome during the pandemic.

121 42 patients were diagnosed with Guillain-Barre syndrome during the study period.

122 n, and 3 patients had complete resolution of Guillain-Barre syndrome following therapy.

123 oisson-based analysis to compare the risk of Guillain-Barre syndrome following vaccination in each se

124 ination in the six weeks before the onset of Guillain-Barre syndrome for 19 patients.

125 ed risk interval analysis of chart-confirmed Guillain-Barre syndrome found an elevated but not statis

126 o increase in the risk of vaccine-associated Guillain-Barre syndrome from 1992-1993 to 1993-1994.

127 6 acute flaccid paralysis cases diagnosed as Guillain-Barre syndrome from 2000 through 2008 in childr

128 Guillain Barre syndrome (GBS) is the most common cause o

129 are strongly associated with axonal forms of Guillain Barre syndrome (GBS).

130 Surveillance for Guillain-Barre syndrome (GBS) after receipt of this vacc

131 Guillain-Barre syndrome (GBS) and chronic inflammatory d

132 tis (EAN) is considered the in vivo model of Guillain-Barre syndrome (GBS) and has been extensively s

133 lammatory demyelinating neuropathies such as Guillain-Barre syndrome (GBS) and its animal model, expe

134 and consequences of adult infection include Guillain-Barre syndrome (GBS) and meningoencephalitis.

135 thought to be involved in the triggering of Guillain-Barre syndrome (GBS) and Miller-Fisher syndrome

136 rus was a cause of the neurological disorder Guillain-Barre syndrome (GBS) and of microcephaly and ot

137 1 vaccine) and the prior association between Guillain-Barre syndrome (GBS) and the 1976 H1N1 influenz

138 Americas has been associated with a surge in Guillain-Barre syndrome (GBS) cases.

139 ylobacter jejuni isolated from patients with Guillain-Barre syndrome (GBS) differ from isolates isola

140 5 days of symptom onset on 369 patients with Guillain-Barre Syndrome (GBS) enrolled in a trial compar

141 An increased risk of Guillain-Barre syndrome (GBS) following administration o

142 Given the increased risk of Guillain-Barre Syndrome (GBS) found with the 1976 swine

143 Guillain-Barre syndrome (GBS) has been associated with s

144 Guillain-Barre syndrome (GBS) has been reported to be as

145 tween Campylobacter infection and subsequent Guillain-Barre syndrome (GBS) has been well documented.

146 national morbidity and mortality burden for Guillain-Barre syndrome (GBS) in the United States, a na

147 Guillain-Barre syndrome (GBS) is a postinfectious autoim

148 Guillain-Barre syndrome (GBS) is a postinfectious neurop

149 Guillain-Barre syndrome (GBS) is an acute inflammatory d

150 Guillain-Barre syndrome (GBS) is an acute polyradiculone

151 Guillain-Barre syndrome (GBS) is an acute polyradiculopa

152 Guillain-Barre syndrome (GBS) is an acute postinfectious

153 Guillain-Barre syndrome (GBS) is an autoimmune disease c

154 Guillain-Barre syndrome (GBS) is an immune-mediated peri

155 te motor axonal neuropathy (AMAN) variant of Guillain-Barre syndrome (GBS) is associated with anti-GD

156 Guillain-Barre Syndrome (GBS) is believed to be caused b

157 asonal variation in incidence and subtype of Guillain-Barre syndrome (GBS) is contradictory, but has

158 Guillain-Barre syndrome (GBS) is the most common cause o

159 An unexplained increase in the risk of Guillain-Barre syndrome (GBS) occurred among recipients

160 are specific to O serotypes associated with Guillain-Barre syndrome (GBS) or whether they are freque

161 Clinically, Guillain-Barre syndrome (GBS) predominated among regions

162 a exchanges and intravenous immunoglobulins, Guillain-Barre syndrome (GBS) still carries non-negligib

163 tigenic targets of autoantibodies present in Guillain-Barre syndrome (GBS), a group of neuropathies w

164 oenteritis and often precedes development of Guillain-Barre syndrome (GBS), a life-threatening paraly

165 Guillain-Barre syndrome (GBS), a neurologic disease char

166 Guillain-Barre syndrome (GBS), a neurologic disease that

167 Guillain-Barre syndrome (GBS), an acute, immune-mediated

168 Guillain-Barre syndrome (GBS), an autoimmune disorder of

169 resent in patients with the motor variant of Guillain-Barre syndrome (GBS), and their pathological ro

170 been shown to be an antecedent infection in Guillain-Barre syndrome (GBS), but the clinical spectrum

171 Data on AFP, including Guillain-Barre syndrome (GBS), could be analyzed from a

172 The pathogenesis of Guillain-Barre syndrome (GBS), especially the classic in

173 V infection among patients hospitalized with Guillain-Barre syndrome (GBS), meningoencephalitis, or t

174 sociated with acute immune neuropathy called Guillain-Barre syndrome (GBS).

175 are being explored in myasthenia gravis and Guillain-Barre syndrome (GBS).

176 h the development of the neurologic disorder Guillain-Barre syndrome (GBS).

177 ated in the pathogenesis of some variants of Guillain-Barre syndrome (GBS).

178 in the pathogenesis of Campylobacter-induced Guillain-Barre syndrome (GBS).

179 HS:19 is associated with the development of Guillain-Barre syndrome (GBS).

180 mmune attack is different in the subtypes of Guillain-Barre syndrome (GBS).

181 cacy and anticipate outcome in patients with Guillain-Barre syndrome (GBS).

182 ysiologic features similar to those of human Guillain-Barre syndrome (GBS).

183 ested as essential for accurate diagnosis in Guillain-Barre syndrome (GBS).

184 ediate the postinfectious paralytic disease, Guillain-Barre syndrome (GBS).

185 upport the hypothesis that C. jejuni induces Guillain-Barre syndrome (GBS); however, many questions a

186 d chronic autoimmune neuropathies, including Guillain-Barre syndromes (GBS) are often characterized b

187 risk of neurologic complications (including Guillain-Barre syndrome [GBS]) with ZIKV infection.

188 In 20 of these 42 patients (48%), the Guillain-Barre syndrome had a parainfectious onset.

189 41 (98%) patients with Guillain-Barre syndrome had anti-Zika virus IgM or IgG,

190 Patients with Guillain-Barre syndrome had electrophysiological finding

191 39 (93%) patients with Guillain-Barre syndrome had Zika virus IgM and 37 (88%)

192 ni infections with subsequent development of Guillain-Barre syndrome has increased concerns from a pa

193 ed by an immune attack on the axon ("axonal" Guillain-Barre syndrome) has been advanced primarily bas

194 de of action, and roles of complement in the Guillain-Barre syndrome have been controversial.

195 The concepts of Guillain-Barre syndrome have changed substantially over

196 About a quarter of patients with Guillain-Barre syndrome have had a recent Campylobacter

197 IKV) and neurologic complications, including Guillain-Barre syndrome in adults and CNS abnormalities

198 quito-borne pathogen that has been linked to Guillain-Barre syndrome in adults and congenital microce

199 Zika virus infection could also cause Guillain-Barre syndrome in adults.

200 ital malformations, and its association with Guillain-Barre syndrome in adults.

201 s ability to cause microcephaly in utero and Guillain-Barre syndrome in adults.

202 to devastating congenital birth defects and Guillain-Barre syndrome in adults.

203 ngenital malformations in infants as well as Guillain-Barre syndrome in adults.

204 e occurrence of microcephaly in neonates and Guillain-Barre syndrome in adults.

205 Guillain-Barre syndrome in northern China occurs in two

206 Patients given a diagnosis of the Guillain-Barre syndrome in the 1992-1993 and 1993-1994 i

207 racterized the clinical features of cases of Guillain-Barre syndrome in the context of this ZIKV infe

208 rican and the Caribbean be used to establish Guillain-Barre syndrome incidence rates.

209 re associated with a small increased risk of Guillain-Barre syndrome (incidence rate ratio 2.35, 95%

210 neuropathies include sensory variants of the Guillain-Barre syndrome, including Miller-Fisher syndrom

211 e motor axonal neuropathy (AMAN) form of the Guillain-Barre syndrome is a paralytic disorder of abrup

212 Guillain-Barre syndrome is a rare but serious health dis

213 The motor axonal variant of Guillain-Barre syndrome is associated with anti-GD1a imm

214 Guillain-Barre syndrome is now recognized as a heterogen

215 Guillain-Barre syndrome is the most common and most seve

216 Inflammatory demyelination of nerve in Guillain-Barre syndrome is triggered in most patients by

217 il and its association with microcephaly and Guillain-Barre syndrome led to accelerated vaccine devel

218 its likely association with microcephaly and Guillain-Barre syndrome make Zika an urgent public healt

219 als, IVIg has been effective in treating the Guillain-Barre syndrome, multifocal motor neuropathy, ch

220 spinal fluid ("drop metastases") (n = 18) or Guillain-Barre syndrome (n = 1).

221 yelinating polyradiculoneuropathy (n=53) and Guillain-Barre syndrome (n=21).

222 res (n = 44), meningitis (n = 3), and other (Guillain-Barre Syndrome) (n = 1).

223 f human immunoglobulin in an animal model of Guillain-Barre syndrome, namely experimental autoimmune

224 In Guillain-Barre syndrome, newly described antibodies bind

225 Possible associations with microcephaly and Guillain-Barre syndrome observed in this outbreak have r

226 in a demyelinating neuropathy that may mimic Guillain-Barre syndrome or chronic inflammatory demyelin

227 an sural nerves and those from patients with Guillain-Barre syndrome or chronic inflammatory demyelin

228 invasion), neuromuscular complications (eg, Guillain-Barre syndrome or transient muscle dysfunctions

229 o pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis).

230 ctic serious allergic reaction, anaphylaxis, Guillain-Barre syndrome, or invasive Hib disease.

231 the paralytic form, which closely resembles Guillain-Barre syndrome, or when a patient is comatose a

232 ding translated to about 1.6 excess cases of Guillain-Barre syndrome per million people vaccinated.

233 ts slightly more than one additional case of Guillain-Barre syndrome per million persons vaccinated a

234 os and attributable risks of excess cases of Guillain-Barre syndrome per million vaccinations.

235 The long-term sequelae (Guillain-Barre syndrome, reactive arthritis, and postinf

236 f glycosylated flagellin with development of Guillain-Barre syndrome remains speculative, but the pos

237 Guillain-Barre syndrome remains the most frequent neurol

238 lity that such cases of motor-sensory axonal Guillain-Barre syndrome represent the most severe end of

239 virus (ZIKV), which causes microcephaly and Guillain-Barre syndrome, signals an urgency to identify

240 emic lupus erythematosus, myasthenia gravis, Guillain-Barre syndrome, skin blistering syndromes, and

241 Highly visible health conditions, such as Guillain-Barre syndrome, spontaneous abortion, or even d

242 In the Guillain-Barre syndrome subform acute motor axonal neuro

243 site-specific injury in acute AGAb-mediated Guillain-Barre syndrome subforms and their chronic count

244 te motor axonal neuropathy (AMAN), a form of Guillain-Barre syndrome that selectively affects motor n

245 re frequently than expected in patients with Guillain-Barre syndrome, this association is extremely r

246 eports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly.

247 r of reports of influenza-vaccine-associated Guillain-Barre syndrome to the national Vaccine Adverse

248 ipid reactivity was studied in patients with Guillain-Barre syndrome using both ELISA and combinatori

249 mptoms of ZIKV infection and symptoms of the Guillain-Barre syndrome was 7 days (interquartile range,

250 ecember 1976 after an increased incidence of Guillain-Barre syndrome was attributed to the vaccine.

251 smitted, and an increase in the incidence of Guillain-Barre syndrome was reported in some countries d

252 During the same period, an increase in Guillain-Barre syndrome was reported, suggesting a possi

253 through March 2016, clusters of cases of the Guillain-Barre syndrome were observed during the outbrea

254 study did not control for infection prior to Guillain-Barre syndrome, which may have been a confounde

255 oneuropathy and in none of the patients with Guillain-Barre syndrome, which was confirmed by cell bin

256 nant women, their infants, and patients with Guillain-Barre syndrome who had traveled to areas with Z

257 In 18 of 42 patients (43%) with the Guillain-Barre syndrome who underwent laboratory testing

258 series method to investigate the relation of Guillain-Barre syndrome with influenza vaccine and influ

259 The severe, generalised manifestation of Guillain-Barre syndrome with respiratory failure affects

260 An association of Guillain-Barre syndrome with TNFalpha antagonist therapy

261 In contrast, the relative incidence of Guillain-Barre syndrome within 90 days of an influenzali

262 The relative incidence of Guillain-Barre syndrome within 90 days of vaccination wa

263 g microcephaly, congenital malformation, and Guillain-Barre syndrome, Zika virus (ZIKV) remains a per